Eli Lilly’s Trulicity (dulaglutide) Receives the US FDA’s Approval to Reduce MACE in T2D Adults

 Eli Lilly’s Trulicity (dulaglutide) Receives the US FDA’s Approval to Reduce MACE in T2D Adults

Eli Lilly’s Alimta (pemetrexed) + Keytruda (pembrolizumab) Receives FDA’s Expanded Label Approval for 1L Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Shots:

  • The approval follows the REWIND study which involves assessing of Trulicity + SoC (1.5mg) vs PBO + SoC in adults with T2D
  • The study showed reduction in MACE events and the profile of Trulicity was consistent with the GLP-1 receptor agonist (RA) class
  • Trulicity is an injectable prescription medicine for adults with T2D used for the improving blood sugar level and reduction of MACE

Click here to read full press release/ article | Ref: Eli Lilly | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post